Table 1.

Patient and donor characteristics (N = 35)

Patient and disease characteristicValue
Median age (range), y 62 (20-74) 
Sex, n (%)  
 Male 21 (60) 
 Female 14 (40) 
Diagnosis, n(%)  
 Mycosis fungoides 13 (37) 
  Stage IIB* 7 (20) 
  Stage IVA 6 (17) 
  Large cell transformation 12 (34) 
   Skin only 8 (23) 
   Skin plus extracutaneous site 4 (11) 
 Sézary syndrome 22 (63) 
  Stage IVA 17 (49) 
  IVB 5 (14) 
  Large cell transformation 8 (23) 
   Skin only 3 (9) 
   Extracutaneous site only 3 (9) 
   Skin plus extracutaneous site 2 (5) 
Retro-CLIPI, n (%)  
 High risk 18 (52) 
 Intermediate risk 13 (37) 
 Low risk 4 (11) 
Time from diagnosis to allogeneic HCT, median (range), mo 40 (9-152) 
 <24, n (%) 12 (34) 
 ≥24, n (%) 23 (66) 
No. of previous systemic therapies, median (range) 5 (2-13) 
Active disease at the time of conditioning, n (%)  
 Skin 35 (100) 
 Blood 12 (34) 
 Lymph node 22 (63) 
 Visceral 5 (14) 
Donor, n (%)  
 Sibling 13 (37) 
 Unrelated 22 (63) 
  Matched 15 (43) 
  Mismatched§ 7 (20) 
Donor–recipient CMV status, n (%)  
 Donor and/or recipient seropositive 27 (77) 
 Donor and recipient seronegative 8 (23) 
Patient and disease characteristicValue
Median age (range), y 62 (20-74) 
Sex, n (%)  
 Male 21 (60) 
 Female 14 (40) 
Diagnosis, n(%)  
 Mycosis fungoides 13 (37) 
  Stage IIB* 7 (20) 
  Stage IVA 6 (17) 
  Large cell transformation 12 (34) 
   Skin only 8 (23) 
   Skin plus extracutaneous site 4 (11) 
 Sézary syndrome 22 (63) 
  Stage IVA 17 (49) 
  IVB 5 (14) 
  Large cell transformation 8 (23) 
   Skin only 3 (9) 
   Extracutaneous site only 3 (9) 
   Skin plus extracutaneous site 2 (5) 
Retro-CLIPI, n (%)  
 High risk 18 (52) 
 Intermediate risk 13 (37) 
 Low risk 4 (11) 
Time from diagnosis to allogeneic HCT, median (range), mo 40 (9-152) 
 <24, n (%) 12 (34) 
 ≥24, n (%) 23 (66) 
No. of previous systemic therapies, median (range) 5 (2-13) 
Active disease at the time of conditioning, n (%)  
 Skin 35 (100) 
 Blood 12 (34) 
 Lymph node 22 (63) 
 Visceral 5 (14) 
Donor, n (%)  
 Sibling 13 (37) 
 Unrelated 22 (63) 
  Matched 15 (43) 
  Mismatched§ 7 (20) 
Donor–recipient CMV status, n (%)  
 Donor and/or recipient seropositive 27 (77) 
 Donor and recipient seronegative 8 (23) 
*

Highest staging before allogeneic hematopoietic cell transplantation (HCT).

Retro-CLIPI.35 

Visceral sites: 4 bone marrow, 1 tonsil.

§

All had single HLA mismatches.

Close Modal

or Create an Account

Close Modal
Close Modal